VYNDAMAX Drug Patent Profile

When do Vyndamax patents expire, and when can generic versions of Vyndamax launch?

Vyndamax is a drug marketed by Foldrx Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-six patent family members in twenty-seven countries.

The generic ingredient in VYNDAMAX is tafamidis. One supplier is listed for this compound. Additional details are available on the tafamidis profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyndamax

Vyndamax was eligible for patent challenges on May 3, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2026. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VYNDAMAX

International Patents:	66
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	70
Patent Applications:	262
Drug Prices:	Drug price information for VYNDAMAX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYNDAMAX
DailyMed Link:	VYNDAMAX at DailyMed

See drug prices for VYNDAMAX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYNDAMAX

Constraining patent/regulatory exclusivity:

7,214,695

NDA:

212161

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for VYNDAMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYNDAMAX	Capsules	tafamidis	61 mg	212161	3	2023-05-03

US Patents and Regulatory Information for VYNDAMAX

VYNDAMAX is protected by three US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 7,214,695.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Foldrx Pharms	VYNDAMAX	tafamidis	CAPSULE;ORAL	212161-001	May 3, 2019		RX	Yes	Yes	9,770,441		Y	Y
Foldrx Pharms	VYNDAMAX	tafamidis	CAPSULE;ORAL	212161-001	May 3, 2019		RX	Yes	Yes
Foldrx Pharms	VYNDAMAX	tafamidis	CAPSULE;ORAL	212161-001	May 3, 2019		RX	Yes	Yes	7,214,696
Foldrx Pharms	VYNDAMAX	tafamidis	CAPSULE;ORAL	212161-001	May 3, 2019		RX	Yes	Yes	7,214,695		Y	Y

EU/EMA Drug Approvals for VYNDAMAX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Vyndaqel	tafamidis	EMEA/H/C/002294Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.	Authorised	no	no	yes	2011-11-16

International Patents for VYNDAMAX

See the table below for patents covering VYNDAMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2010270134	COMPOSITION AND METHOD FOR STABILIZING TRANSTHYRETIN AND INHIBITING MISFOLDING OF TRANSTHYRETIN
Cyprus	1108467
Luxembourg	91935
World Intellectual Property Organization (WIPO)	2016038500
Denmark	1988397
Spain	2901785

Supplementary Protection Certificates for VYNDAMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1587821	C01587821/01	Switzerland		PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67083 09.03.2020
1587821	C20120001 00050	Estonia		PRODUCT NAME: VYNDAQEL - TAFAMIDIS;REG NO/DATE: C(2011)8519 FINAL 16.11.2011
1587821	C 2012 004	Romania		PRODUCT NAME: TAFAMIDISMEGLUMINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/717/001; DATE OF NATIONAL AUTHORISATION: 20111116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/717/001; DATE OF FIRST AUTHORISATION IN EEA: 20111116
1587821	126 5003-2012	Slovakia		PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116
1587821	91935	Luxembourg		91935, EXPIRES: 20261116
1587821	382	Finland

VYNDAMAX market dynamics and financial trajectory: VYNDAMAX (vutrisiran) sales, exclusivity, biosimilar and generic risk, and patent estate outlook

Last updated: May 29, 2026

VYNDAMAX (vutrisiran) generates revenue tied to the hereditary transthyretin amyloidosis (ATTRv) treatment base for polyneuropathy. Market dynamics depend on (1) disease-modifying access and payer contracting, (2) competitive pressure from competing TTR stabilizers and gene silencers, and (3) time-to-loss of exclusivity for vutrisiran’s branded indications and formulation/administration IP. Financial trajectory is best modeled around treated-patient growth, dose retention, and channel mix, with higher volatility in later quarters when payer step edits and channel consolidations occur.

What is VYNDAMAX (vutrisiran) and how is it positioned in ATTRv polyneuropathy?

VYNDAMAX is a targeted RNA-silencing therapy for ATTRv amyloidosis affecting polyneuropathy. In-market positioning rests on a chronic, life-long treatment paradigm and on achieving neurologic stabilization compared with supportive care.

What patient segments drive VYNDAMAX volume?

Key volume drivers typically include:

• Newly diagnosed ATTRv polyneuropathy patients entering treatment
• Patients switching from tafamidis or other TTR-directed strategies due to access, payer coverage, or efficacy/tolerability goals
• Retention of existing treated cohorts based on adverse event management and infusion/clinic workflows

Where does VYNDAMAX compete most directly?

• Other ATTR-directed disease-modifying therapies (notably TTR stabilizers such as tafamidis)
• Alternative RNA-silencing or gene-regimen entrants depending on geography and uptake

What market dynamics determine VYNDAMAX uptake and payer adoption?

VYNDAMAX’s uptake is shaped by reimbursement mechanics, specialty pharmacy distribution, and center-of-excellence prescribing. In specialty drugs for rare diseases, revenue growth is highly sensitive to contract status and patient access programs.

How do payer rules and utilization management affect net sales?

Revenue line items often reflect:

• Prior authorization and step therapy enforcement
• Specialty pharmacy carve-outs and rebate structures
• Coverage tiers and exclusion lists for non-preferred drugs within ATTRv

What role do treatment logistics play in switching and retention?

Vutrisiran administration pathways influence persistence and switching:

• Infusion or clinical administration capacity at specialty centers
• Patient adherence driven by scheduled dosing and clinic availability
• Burden-of-care tradeoffs versus oral comparators in payer communications

How do disease diagnostics and referral patterns affect new starts?

New-start velocity tracks with:

• Increased genetic screening and improved ATTRv referral pathways
• Neurology and cardiology clinic referral conversion into infusion-ready care pathways

How strong is the exclusivity timeline for VYNDAMAX and when does it lose exclusivity?

Financial trajectory depends on the timing of exclusivity loss and the risk of generic or biosimilar entry. For RNA therapeutics, market exclusivity risk is typically dominated by composition, use, and formulation IP rather than a simple Orange Book “expiration” model like small molecules.

What exclusivity levers matter for VYNDAMAX?

• Patent life for active ingredient and RNA platform chemistry
• Patent coverage for specific therapeutic use (ATTRv polyneuropathy and related disease-state parameters)
• Formulation and administration-related patents (dose delivery, stabilizers, packaging, infusion-related processes)

What does “loss of exclusivity” mean in practice for VYNDAMAX revenue?

Even if regulatory exclusivity ends, practical revenue erosion depends on:

• Successful challenge outcomes (if any) and launch readiness
• Payer contracting for alternatives
• Real-world discontinuation rates from brand switching after entry

Which patents protect VYNDAMAX (vutrisiran) and what is the patent estate coverage strategy?

A meaningful financial risk assessment requires mapping the patent estate by IP type:

• Composition and manufacturing of the RNA therapeutic
• Medical-use patents for ATTRv neurologic manifestations
• Formulation and delivery system patents controlling stability and dosing performance

How to read the estate for revenue risk

The most revenue-relevant patents are typically:

• Those covering label indications (method-of-use)
• Those that can block a “carve-out” launch
• Those tied to formulation that constrain bioequivalence or interchangeability arguments

Jurisdiction and enforcement scope that drive monetization

For a global revenue base, enforceability and filing coverage across major markets (US, EU5, UK, Japan) are central to:

• Settlement leverage
• Launch timing constraints
• Import/export litigation risk

What generic entry risks exist for VYNDAMAX, and how likely is biosimilar-style competition?

Vutrisiran is a biologics-adjacent modality (RNA-based therapeutic). Entry dynamics do not follow the classic ANDA pathway used by small molecules.

Are there generic or substitute risks that could erode VYNDAMAX pricing?

Revenue pressure typically comes from:

• New RNA silencers or competing TTR-directed drugs with label overlap
• Biosimilar-like substitution only if regulatory frameworks and scientific comparability allow, which depends on modality classification

What is the competitive switching risk after entry?

Switching risk rises when:

• Payers negotiate lower net prices for “preferred” therapies
• Providers face co-pay and prior authorization incentives
• Outcomes data supports comparable benefit in real-world settings

What is the Orange Book status of VYNDAMAX and does it signal launch timing?

Orange Book status is relevant only if an application is listed under the Hatch-Waxman framework. For RNA therapeutics, the key practical signal is whether exclusivity and patents are listed and how the listed patents align to the label.

How Orange Book listings typically affect Paragraph IV strategy

If relevant patents are Orange Book listed, a challenge can target specific listed patents. Revenue erosion depends on:

• Whether courts enjoin launch
• Settlement terms that delay entry
• Carve-out rules allowing partial label launches

What patent litigation affects VYNDAMAX and how do outcomes impact financial trajectory?

Patent litigation outcomes can shift financial trajectory through:

• Automatic or negotiated stays of entry
• Adverse court rulings that accelerate competitive launches
• Settlement terms that cap downside via delayed competition

Which litigation events matter most to investors

• Complaint filings and early injunction decisions
• Claim construction rulings
• Final judgments affecting enforceability of key claims
• Consent decrees or stipulated dismissals tied to a launch timetable

What is VYNDAMAX’s commercial trajectory: where does revenue growth come from?

For rare-disease, high-value specialty therapies, VYNDAMAX revenue typically tracks:

• New-treated patient starts
• Dose retention and persistence through multi-quarter treatment cycles
• Pricing dynamics, including payer mix and net-to-gross contraction/expansion

What are the primary unit economics variables?

• Average net price per treated patient (rebates, discounts, patient assistance)
• Treatment cycle persistence and discontinuation rates
• Average sales per patient by geography and payer class

What revenue growth patterns are typical after launch?

Common phases for specialty rare disease drugs:

• Launch scaling phase driven by early adoption and center conversion
• Expansion phase driven by contracting and broader provider uptake
• Maturity phase where volume growth slows and pricing and mix dominate

How does VYNDAMAX compare with competing ATTRv therapies on market and IP risk?

The key comparison for market dynamics is not only clinical differentiation, but also commercial and legal headwinds.

How does pricing pressure differ versus oral therapies?

Oral competitors often carry:

• Different payer preference frameworks (step edits, formulary tiering)
• Lower administration costs and potentially different rebate schedules RNA therapies often trade off administration infrastructure with perceived efficacy, shaping net pricing.

What is the competitive moat in practice?

Commercial moat usually rests on:

• Physician confidence in safety/efficacy
• Established clinic workflows
• Contracted payer coverage status

How does VYNDAMAX’s financial trajectory vary by geography?

Revenue mix typically depends on:

• Coverage policies and rare disease reimbursement frameworks
• Diagnostic density and ATTRv referral patterns
• Local IP enforcement intensity and litigation pace

Key financial and market indicators to monitor for VYNDAMAX

For business planning and valuation, the highest-yield KPIs are:

• Treated patient count and net new starts by quarter
• Net-to-gross trends (rebates, discounts, patient assistance)
• Payer coverage changes (PA denials and step therapy tightening)
• Dose persistence and discontinuation trends
• Any entry signals from competing RNA agents or TTR-directed drugs

Key Takeaways

• VYNDAMAX revenue trajectory depends on treated-patient growth, persistence, and net pricing mechanics more than headline list price.
• Market dynamics are dominated by payer contracting, prior authorization behavior, and logistics-driven adoption through specialized infusion pathways.
• Exclusivity and patent estate timing are the primary drivers of future competitive entry risk, with financial impact tied to litigation outcomes and settlement-led launch schedules.
• Competitive pressure is most likely from modality-similar ATTR-directed agents and from TTR stabilizers through payer preference shifts, not from a straightforward small-molecule generic model.
• Ongoing monitoring should focus on treated patient KPits, net-to-gross compression or expansion, and any regulatory or litigation signals affecting entry timelines.

FAQs

1. How do prior authorization and step edits typically impact VYNDAMAX net sales growth?
2. What treated-patient KPIs best predict VYNDAMAX quarterly revenue changes?
3. What patent categories are most likely to block a VYNDAMAX launch by a competing RNA-silencing therapy?
4. How do settlement agreements in similar specialty biologic/IP disputes translate into delayed competition for VYNDAMAX?
5. Which payer contracting signals indicate that VYNDAMAX is becoming preferred or non-preferred within ATTRv formularies?

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA. Drugs@FDA: VYNDAMAX (as applicable). https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. FDA. Purple Book: Program for Product Discontinuation and Interchangeability. https://purplebooksearch.fda.gov/
4. European Medicines Agency. EPAR documents and assessment reports for vutrisiran and related therapies. https://www.ema.europa.eu/